Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antimicrobial adjustment in pediatric cancer patients with febrile neutropenia and fever of unknown origin
RBR-97gppbrPhase 4Completed
- Sponsor
- Universidad de Chile
- Start
- Mar 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of meropenem and vancomycin in febrile neutropenia (FN) and fever of unknown origin (FUO) (6 arms), sponsored by Universidad de Chile. Primary endpoint: Resolution without complications. Started Mar 2021; status: completed.
02
Drugs
meropenemvancomycin
03
Conditions
febrile neutropenia (FN)fever of unknown origin (FUO)
Beyond the preview
Go deeper on RBR-97gppbr.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-97gppbr.